Future Virology,
Journal Year:
2023,
Volume and Issue:
18(9), P. 595 - 609
Published: June 1, 2023
Respiratory
syncytial
virus
(RSV)
is
a
leading
cause
of
respiratory
illnesses
that
primarily
affects
children,
particularly
those
under
2
years
old,
and
adults.
RSV
infections
can
lead
to
hospitalization
even
mortality.
The
transmitted
through
droplets
spread
by
coughing
or
sneezing.
We
conducted
an
extensive
literature
search
focused
on
RSV,
pathogenicity
relevant
keywords
like
'RSV
treatment,'
vaccine,'
diagnosis'
explore
effective
treatment
strategies,
advances
in
potential
vaccines
ongoing
clinical
trials,
progress
diagnostic
techniques
for
accurate
timely
detection
infections.
These
findings
are
crucial
developing
appropriate
management
control
measures.
The Lancet Microbe,
Journal Year:
2023,
Volume and Issue:
5(1), P. e52 - e61
Published: Dec. 1, 2023
Metagenomic
next-generation
sequencing
(mNGS)
allows
untargeted
identification
of
a
broad
range
pathogens,
including
rare
or
novel
microorganisms.
Despite
the
recognition
mNGS
as
valuable
diagnostic
tool
for
infections,
most
relevant
indications
this
innovative
strategy
remain
poorly
defined.
We
aimed
to
assess
determinants
positivity
and
clinical
utility
mNGS.
Current Issues in Molecular Biology,
Journal Year:
2023,
Volume and Issue:
45(8), P. 6851 - 6879
Published: Aug. 17, 2023
The
search
for
new
drugs
has
been
greatly
accelerated
by
the
emergence
of
viruses
and
drug-resistant
strains
known
pathogens.
Nucleoside
analogues
(NAs)
are
a
prospective
class
antivirals
due
to
safety
profiles,
which
important
rapid
repurposing
in
fight
against
emerging
Recent
improvements
research
methods
have
revealed
unexpected
details
mechanisms
action
NAs
that
can
pave
way
approaches
further
development
effective
drugs.
This
review
accounts
advanced
techniques
viral
polymerase
targeting,
host
enzyme
targeting
approaches,
prodrug-based
strategies
antiviral
NAs.
Vaccines,
Journal Year:
2023,
Volume and Issue:
11(2), P. 491 - 491
Published: Feb. 20, 2023
Respiratory
syncytial
virus
(RSV)
is
a
major
healthcare
concern,
especially
for
immune-compromised
individuals
and
infants
below
5
years
of
age.
Worldwide,
it
known
to
be
associated
with
incidences
morbidity
mortality
in
infants.
Despite
the
seriousness
issue
continuous
rigorous
scientific
efforts,
no
approved
vaccine
or
available
drug
fully
effective
against
RSV.
The
purpose
this
review
article
provide
insights
into
past
ongoing
efforts
securing
vaccines
therapeutics
readers
will
able
confer
mechanism
existing
therapies
loopholes
that
need
overcome
future
therapeutic
development
A
methodological
approach
was
applied
collect
latest
data
updated
results
regarding
We
outline
throughput
vaccination
technologies
prophylactic
linked
range
approaches
already
(with
limited
use)
those
undergoing
trials
are
included.
Moreover,
important
regimens
used
alone
conjugation
adjuvants
also
briefly
discussed.
After
reading
article,
audience
understand
current
standing
clinical
management
form
vaccine,
prophylactic,
candidates
An
understanding
biological
behavior
acting
as
reason
behind
lack
RSV
developed.
literature
indicates
limitations
attached
management,
drugs,
could
explained
by
dealing
challenges
study
designs
improvement
further
work
approval
on
novel
applications.
Frontiers in Virology,
Journal Year:
2023,
Volume and Issue:
3
Published: April 6, 2023
RNA
viruses
encode
an
RNA-dependent
polymerase
(RdRp),
which
is
essential
for
transcription
and
replication
of
their
genome
since
host
cells
lack
equivalent
enzymes.
RdRp
residues
were
shown
to
be
phosphorylated
by
kinases
in
several
human,
animal
or
plant
including
flaviviruses,
picornaviruses,
coronaviruses,
influenza
tymoviruses.
RdRps
can
on
distinct
kinases.
Phosphomimetic
mutations
identified
either
positively
negatively
regulate
synthesis
association
with
other
proteins.
Interestingly,
some
evolved
recruit
cellular
through
direct
protein-protein
interaction,
likely
promote
tightly
control
own
phosphorylation.
Given
the
nature
virus
replication,
a
better
knowledge
RdRps’
phosphorylation
expected
facilitate
design
future
drugs
that
strongly
affect
activity.
Afro-Egyptian Journal of Infectious and Endemic Diseases,
Journal Year:
2023,
Volume and Issue:
0(0), P. 0 - 0
Published: Sept. 24, 2023
Background
and
study
aim:
Since
both
SARS-CoV-2
Hepatitis
C
virus
(HCV)
are
positive-sense
RNA
viruses,
it
is
logical
to
consider
those
nucleotide
analogues
found
be
successful
against
HCV
could
potentially
demonstrate
similar
efficacy
severe
acute
respiratory
syndrome-coronavirus-2
(SARS-CoV-2).
The
present
aims
at
estimating
the
frequency
severity
of
COVID-19
in
HCV-treated
patients.
Patients
Methods:
Cross-sectional
was
accomplished.
enrolled
200
HCV-infected
individuals
who
were
eligible
for
DAADs
therapy
had
received
treatment
2019
before
pandemic.
regimen
all
patients
consisted
Sofosbuvir
plus
Daclatasvir
a
duration
3
months,
except
three
same
6
months
as
result
liver
cirrhosis.
Results:
attained
mean
age
53.6
years.
Most
(74%)
came
from
rural
areas,
forty-seven
(23.5%)
different
chronic
diseases,
with
hypertension
(17.5%)
diabetes
mellitus
(13%)
being
most
common.
majority,
183
(91.5%),
achieved
sustained
virological
response
(SVR).
Only
12
(6%)
developed
COVID-19.
In
(75%),
infection
till
seroconversion
10
days.
All
current
study,
ultimately
improved
no
mortality.
Nine
(75%)
infected
one
year
after
last
dose
DAADs.
rarely
follow
recommended
hygienic
measures.
Conclusion
recommendations:
Previous
hepatitis
by
provides
protection
SARS-CoV-2.
Future
large,
randomized
trials
warranted
draw
firm
conclusions.
Molecular Diversity,
Journal Year:
2024,
Volume and Issue:
28(4), P. 2681 - 2688
Published: June 27, 2024
A
novel
series
of
benzenesulfonamide
substituted
spirothiazolidinone
derivatives
(3a-j)
were
synthesized,
characterized
and
evaluated
for
their
antiviral
activity.
The
spirocyclic
compounds
prepared
by
the
condensation
4-(aminosulfonyl)-2-methoxybenzohydrazide,
appropriate
cyclic
ketones
2-mercaptopropionic
acid
in
a
one-pot
reaction.
structures
new
established
IR,
bioRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 25, 2024
Nucleoside
analogues
are
a
class
of
well-established
antiviral
agents
that
act
by
being
directly
incorporated
into
the
viral
genome
during
replication
process,
resulting
in
chain
termination
or
induction
lethal
mutations.
While
many
nucleoside
have
exhibited
broad-spectrum
activity
against
wide
range
viruses,
their
effectiveness
SARS-CoV-2
is
limited.
The
lack
hypothesized
to
be
attributed
proofreading
function
nsp14
exonuclease.
In
this
study,
role
modulating
was
investigated
using
genetic
and
pharmacological
approaches.
Introduction
exonuclease
attenuation
disabling
mutations
led
either
severe
defect
increased
sensitivity
SARS-CoV
replicons
specific
analogues.
contrast,
repurposing
HCV
NS5A
inhibitors
suppress
insufficient
enhance
potency
These
findings
provided
further
support
for
as
target
development
highlighted
complex
interplay
between
RNA
replication.